IDEAS home Printed from https://ideas.repec.org/a/bla/ijhplm/v32y2017i2pe232-e260.html
   My bibliography  Save this article

The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?

Author

Listed:
  • W. Dominika Wranik
  • Liesl Gambold
  • Natasha Hanson
  • Adrian Levy

Abstract

No abstract is available for this item.

Suggested Citation

  • W. Dominika Wranik & Liesl Gambold & Natasha Hanson & Adrian Levy, 2017. "The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?," International Journal of Health Planning and Management, Wiley Blackwell, vol. 32(2), pages 232-260, April.
    • Handle: RePEc:bla:ijhplm:v:32:y:2017:i:2:p:e232-e260
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1002/hpm.2372
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Franken, Margreet & Stolk, Elly & Scharringhausen, Tessa & de Boer, Anthonius & Koopmanschap, Marc, 2015. "A comparative study of the role of disease severity in drug reimbursement decision making in four European countries," Health Policy, Elsevier, vol. 119(2), pages 195-202.
    2. Margreet Franken & Fredrik Nilsson & Frank Sandmann & Anthonius Boer & Marc Koopmanschap, 2013. "Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making," PharmacoEconomics, Springer, vol. 31(9), pages 781-797, September.
    3. Jean Yong & Jaclyn Beca & Jeffrey Hoch, 2013. "The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada," PharmacoEconomics, Springer, vol. 31(3), pages 229-236, March.
    4. Cookson, Richard & Hutton, John, 2003. "Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective," Health Policy, Elsevier, vol. 63(2), pages 167-178, February.
    5. Heather McDonald & Cathy Charles & Laurie Elit & Amiram Gafni, 2015. "Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?," PharmacoEconomics, Springer, vol. 33(3), pages 235-241, March.
    6. Hartz, Susanne & John, Jürgen, 2009. "Public health policy decisions on medical innovations: What role can early economic evaluation play?," Health Policy, Elsevier, vol. 89(2), pages 184-192, February.
    7. Drummond, Michael & Cooke, Jonathan & Walley, Tom, 1997. "Economic evaluation under managed competition: Evidence from the U.K," Social Science & Medicine, Elsevier, vol. 45(4), pages 583-595, August.
    8. Eddama, Oya & Coast, Joanna, 2008. "A systematic review of the use of economic evaluation in local decision-making," Health Policy, Elsevier, vol. 86(2-3), pages 129-141, May.
    9. Boon, Wouter & Martins, Luis & Koopmanschap, Marc, 2015. "Governance of conditional reimbursement practices in the Netherlands," Health Policy, Elsevier, vol. 119(2), pages 180-185.
    10. Williams, Iestyn & Bryan, Stirling, 2007. "Understanding the limited impact of economic evaluation in health care resource allocation: A conceptual framework," Health Policy, Elsevier, vol. 80(1), pages 135-143, January.
    11. Stirling Bryan & Iestyn Williams & Shirley McIver, 2007. "Seeing the NICE side of cost‐effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals," Health Economics, John Wiley & Sons, Ltd., vol. 16(2), pages 179-193, February.
    12. Duthie, Tessa & Trueman, Paul & Chancellor, Jeremy & Diez, Lara, 1999. "Research into the use of health economics in decision making in the United Kingdom--Phase II: Is health economics `for good or evil'?," Health Policy, Elsevier, vol. 46(2), pages 143-157, January.
    13. Hasle-Pham, Elodie & Arnould, Benoit & Spath, Hans-Martin & Follet, Alain & Duru, Gerard & Marquis, Patrick, 2005. "Role of clinical, patient-reported outcome and medico-economic studies in the public hospital drug formulary decision-making process: results of a European survey," Health Policy, Elsevier, vol. 71(2), pages 205-212, February.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Wranik, Wiesława Dominika & Gambold, Liesl & Peacock, Stuart, 2021. "Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland," Health Policy, Elsevier, vol. 125(3), pages 307-319.
    2. Wranik, Wiesława Dominika & Zielińska, Dorota Anna & Gambold, Liesl & Sevgur, Serperi, 2019. "Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland," Health Policy, Elsevier, vol. 123(2), pages 191-202.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Gregory Merlo & Katie Page & Julie Ratcliffe & Kate Halton & Nicholas Graves, 2015. "Bridging the Gap: Exploring the Barriers to Using Economic Evidence in Healthcare Decision Making and Strategies for Improving Uptake," Applied Health Economics and Health Policy, Springer, vol. 13(3), pages 303-309, June.
    2. Williams, Iestyn P. & Bryan, Stirling, 2007. "Cost-effectiveness analysis and formulary decision making in England: Findings from research," Social Science & Medicine, Elsevier, vol. 65(10), pages 2116-2129, November.
    3. Eddama, Oya & Coast, Joanna, 2008. "A systematic review of the use of economic evaluation in local decision-making," Health Policy, Elsevier, vol. 86(2-3), pages 129-141, May.
    4. Legood, Rosa & Wolstenholme, Jane & Gray, Alastair, 2009. "From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap," Health Policy, Elsevier, vol. 89(2), pages 193-200, February.
    5. Wranik, Wiesława Dominika & Zielińska, Dorota Anna & Gambold, Liesl & Sevgur, Serperi, 2019. "Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland," Health Policy, Elsevier, vol. 123(2), pages 191-202.
    6. Hwa-Young Lee & Thuy Thi-Thu Nguyen & Saeun Park & Van Minh Hoang & Woong-Han Kim, 2021. "Health Technology Assessment Development in Vietnam: A Qualitative Study of Current Progress, Barriers, Facilitators, and Future Strategies," IJERPH, MDPI, vol. 18(16), pages 1-13, August.
    7. Eun-Young Bae & Hui Jeong Kim & Hye-Jae Lee & Junho Jang & Seung Min Lee & Yunkyung Jung & Nari Yoon & Tae Kyung Kim & Kookhee Kim & Bong-Min Yang, 2018. "Role of economic evidence in coverage decision-making in South Korea," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    8. Mara Airoldi & Alec Morton & Jenifer A. E. Smith & Gwyn Bevan, 2014. "STAR—People-Powered Prioritization," Medical Decision Making, , vol. 34(8), pages 965-975, November.
    9. Williams, Iestyn & Bryan, Stirling, 2007. "Understanding the limited impact of economic evaluation in health care resource allocation: A conceptual framework," Health Policy, Elsevier, vol. 80(1), pages 135-143, January.
    10. Neale Smith & Craig Mitton & Stuart Peacock, 2009. "Qualitative methodologies in health‐care priority setting research," Health Economics, John Wiley & Sons, Ltd., vol. 18(10), pages 1163-1175, October.
    11. Hoffmann, Christiane AU -, 2000. "The influence of economic evaluation studies on decision making.: A European survey," Health Policy, Elsevier, vol. 52(3), pages 179-192, July.
    12. Elias Asfaw Zegeye & Josue Mbonigaba & Sylvia Blanche Kaye & Thomas Wilkinson, 2017. "Economic Evaluation in Ethiopian Healthcare Sector Decision Making: Perception, Practice and Barriers," Applied Health Economics and Health Policy, Springer, vol. 15(1), pages 33-43, February.
    13. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    14. Ava John-Baptiste & Marilyn M. Schapira & Catherine Cravens & James D. Chambers & Peter J. Neumann & Joanna Siegel & William Lawrence, 2016. "The Role of Decision Models in Health Care Policy," Medical Decision Making, , vol. 36(5), pages 666-679, July.
    15. Abdulaziz Ibrahim Alzarea & Yusra Habib Khan & Abdullah Salah Alanazi & Muhammad Hammad Butt & Ziyad Saeed Almalki & Abdullah K. AlAhmari & Saud Alsahali & Tauqeer Hussain Mallhi, 2022. "Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries," IJERPH, MDPI, vol. 19(13), pages 1-18, June.
    16. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    17. Salas-Vega, Sebastian & Bertling, Annika & Mossialos, Elias, 2016. "A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK," Health Policy, Elsevier, vol. 120(10), pages 1104-1114.
    18. Torbica, Aleksandra & Fattore, Giovanni, 2010. "Understanding the impact of economic evidence on clinical decision making: A discrete choice experiment in cardiology," Social Science & Medicine, Elsevier, vol. 70(10), pages 1536-1543, May.
    19. Grundy, Quinn, 2016. "“Whether something cool is good enough”: The role of evidence, sales representatives and nurses' expertise in hospital purchasing decisions," Social Science & Medicine, Elsevier, vol. 165(C), pages 82-91.
    20. Stirling Bryan & Iestyn Williams & Shirley McIver, 2007. "Seeing the NICE side of cost‐effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals," Health Economics, John Wiley & Sons, Ltd., vol. 16(2), pages 179-193, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:ijhplm:v:32:y:2017:i:2:p:e232-e260. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0749-6753 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.